AMENDMENTS TO THE CLAIMS

1. – 18. (previously cancelled)

19. (currently amended) A method for the treatment of male erectile dysfunction which comprises administering to a male in need thereof a pharmacologically effective amount of a composition comprising an α-adrenergic blocker and a prostaglandin in a buffer**, wherein the buffer comprises a substrate for nitric oxide synthetase**.

20. (original) The method of claim 19 wherein the α-adrenergic blocker is phentolamine mesylate, or any pharmaceutically acceptable salt thereof.

21. (cancelled)

22. (original) The method of claim 19 wherein the prostaglandin is alprostadil.

23. (original) The method of claim 19 wherein the buffer comprises L-arginine and, optionally, a pharmaceutically acceptable excipient or carrier.

24. (original) The method of claim 23 wherein the buffer comprises glycine having a pH range of from about 3 to about 5.

25. (original) The method of claim 19 wherein the buffer comprises a mixture of arginine and glycine having a pH range of from about 3 to about 5.

26. (original) The method of claim 19 wherein the buffer comprises glycine and L-arginine in a weight ratio of about 1:20.

27. (original) The method of claim 25 wherein the buffer further comprises benzyl alcohol and mannitol and has a pH range of from about 3 to about 5.

28. (original) The method of claim 19 wherein the weight ratio of phentolamine mesylate: alprostadil is about 0.5:0.005 to about 5: 0.20.

29. (original) The method of claim 19 wherein the weight ratio of phentolamine mesylate: alprostadil is about 1:0.01.

30. (original) The method of claim 19 wherein the dosage of phentolamine mesylate and alprostadil are in the range of about 0-40 μg/ml alprostadil-and about 0-10 mg/ml phentolamine.

31. (original) The method of claim 19 wherein the dosage of phentolamine mesylate and alprostadil are in the range of about 1.25-5 mg/ml phentolamine and about 5-20 μg/ml alprostadil.

32. (original) The method of claim 19 wherein the dosage of phentolamine mesylate and alprostadil are about 1 mg/ml phentolamine and about 0.01 mg/ml alprostadil.

33. (original) The method of claim 30, 31, or 32 wherein the vasoactive agents are present in a total volume of 0.5 ml.

34. (original) The method of claim 19 wherein the dosage of alprostadil is about 5 μg/ml in a total volume of 0.5 ml.

35. (original) The method of claim 19 wherein the dosage of phentolamine is about 1.25 mg/ml in a total volume of 0.5 ml.

36. (original) The method of claim 19 wherein the pH range of the buffer is from about 3 to about 7.

37. – 46. (previously cancelled)